Is Novo Nordisk's Experimental Obesity Drug Outperforming Semaglutide?

Novo Nordisk A/S and United Laboratories International Holdings Limited reported positive results from a phase 2 trial of UBT251, a triple receptor agonist designed to compete with Eli Lilly's retatrutide. In the trial, UBT251 demonstrated a maximum mean HbA1c reduction of 2.16% and weight loss of up to 9.8%, outperforming semaglutide's 1.77% and 4.8% reductions, respectively. Novo Nordisk plans to initiate a global phase 1b/2a trial for UBT251 in overweight participants, with results expected in 2027, while also preparing for a phase 2 trial in type 2 diabetes in late 2026. As of the latest check, Novo Nordisk's stock was up 0.89% at $37.22.